Using capillaroscopy to help diagnose diffuse interstitial pneumonias

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional project adds nailfold capillaroscopy to the usual diagnostic workup for adults with a recent diagnosis of pulmonary interstitial disease to describe capillaroscopic features in this population. Eligible patients undergo a chart review and any additional tests needed to determine whether their lung disease is linked to a connective tissue disorder, with most diagnostic work completed within three months. Capillaroscopy is a non‑invasive, reproducible test used to detect microvascular changes commonly seen in scleroderma spectrum diseases, and the study will record how often it identifies abnormalities in newly diagnosed patients. The goal is to see whether systematic use of capillaroscopy increases early identification of PID related to connective tissue disease and shortens time to appropriate treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female over 18 years of age;
* Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
* Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);
* French-speaking patient with no comprehension difficulties;
* Person affiliated with or beneficiary of a social security system;
* Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion Criteria:

* Have previously undergone a capillaroscopy, regardless of the reason;
* Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
* Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
* Pregnant or breastfeeding women;
* Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).

Where it's running

• CHU de Bordeaux - service de rhumatologie
  Bordeaux, France Recruiting

Study contacts

• Principal investigator: Marie-Elise TRUCHETET, MD, PhD — University Hospital, Bordeaux
• Study coordinator: Marie-Elise TRUCHETET, MD, PhD
• Email: marie-elise.truchetet@chu-bordeaux.fr
• Phone: 05.56.79.55.56

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of progressive lung fibrosis in connective tissue diseases

  This project will test whether blood extracellular vesicle biomarkers combined with AI-analyzed HRCT scans can detect and predict progressive interstitial lung disease in adults with connective tissue diseases.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07541638

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Using stem cells to treat lung disease in patients with connective tissue disorders

  This study is testing if a new treatment using stem cells can help improve lung function in patients with lung disease caused by connective tissue disorders.

  Recruiting Phase 1/2 China Medical University Hospital · Taichung · NCT06574581

• Registry of patients with connective tissue diseases and lung issues

  This study is collecting health information from patients with connective tissue diseases to see how often they develop lung problems and to understand their treatment over time.

  Recruiting Medical University Innsbruck · Innsbruck · NCT04095351

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.